Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260463 | 0.86 | SIGMAR1 (0.47) | SIGMAR1L3MBTL3 | |
| SCHEMBL260376 | 0.83 | HRH3 (0.42) | HRH3L3MBTL1MBTD1L3MBTL3TDP1 | |
| SCHEMBL260905 | 0.82 | HRH3 (0.46) | HRH3TDP1 | |
| SCHEMBL27965699 | 0.74 | SLC6A3 (0.37) | SLC6A3HRH3SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL260817 | 0.73 | MC4R (0.45) | MPO | |
| SCHEMBL1225211 | 0.73 | DAO (0.51) | SLC6A3HRH3SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL260550 | 0.72 | SLC6A3 (0.44) | SLC6A3HRH3SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL3420960 | 0.72 | HIF1A (0.36) | MPO | |
| SCHEMBL31088978 | 0.70 | HRH3 (0.53) | SLC6A3HRH3SIGMAR1L3MBTL1MBTD1 | |
| SCHEMBL259925 | 0.70 | HRH3 (0.45) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101987848-B | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing the same | SERVIER LAB | 2014-06-18 | — | — | CN | disclosed |
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2281822-B1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-16 | — | — | EP | disclosed |
| US-8133889-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-13 | — | — | US | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | SLC6A3 3993/4885HRH3 922/4885SIGMAR1 1276/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | SLC6A3 3993/4885HRH3 922/4885SIGMAR1 1276/4885 |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | SLC6A3 3993/4885HRH3 922/4885SIGMAR1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.